June 17, 2025
1 min watch
CHICAGO — On this video, Susana M. Campos, MD, MPH, discusses outcomes from a part 2 trial of pembrolizumab and lenvatinib for sufferers with recurrent or persistent clear-cell ovarian most cancers.
Findings from the single-arm, two-stage trial of mixture pembrolizumab (Keytruda, Merck) and lenvatinib (Lenvima, Eisai), which evaluated goal response charge and PFS at 6 months, had been offered at ASCO Annual Assembly.
“This confirmed an general response charge of 36.7%, which is definitely significant,” Campos, scientific director of the division of gynecologic oncology at Dana-Farber Most cancers Institute and assistant professor of drugs at Harvard Medical Faculty, mentioned. “It’s a good way to have the ability to goal sure kinds of ovarian most cancers — on this specific setting, a transparent cell — and supply one thing to ladies that’s completely completely different than what we’ve had earlier than.”
Reference:
Lee AK, et al. Summary 5515. Introduced at: ASCO Annual Assembly; Might 30-June 3, 2025; Chicago.
